NI
75
2
V
60
-6
UHS
54
3
MTCH
37
7
DVA
72
2
HD
47
-5
IFF
53
2
DOV
61
-2
COST
58
-2
PRU
57
-3
XEL
67
2
ED
48
3
CSCO
63
2
SCHW
64
2
AIG
38
-4
NWS
62
-2
VTR
49
-3
HP
38
-2
ORLY
53
-3
AES
39
-4
NI
75
2
V
60
-6
UHS
54
3
MTCH
37
7
DVA
72
2
HD
47
-5
IFF
53
2
DOV
61
-2
COST
58
-2
PRU
57
-3
XEL
67
2
ED
48
3
CSCO
63
2
SCHW
64
2
AIG
38
-4
NWS
62
-2
VTR
49
-3
HP
38
-2
ORLY
53
-3
AES
39
-4
Financhill
Back

Structure Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.25/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
26

GPCR
Structure Therapeutics

Last Price:
30.10
Seasonality Move:
-11.15%

7 Day Trial

ALL ACCESS PASS

$ 7

Start Investing Smarter Unlock Louis Navellier's Stock Grader for free

Louis' clients have paid up to $30,000 for these insights - now you can try it at no cost.

Structure Therapeutics Price Quote

$30.10
-2.61 (-7.98%)
(Updated: November 21, 2024 at 5:55 PM ET)

Structure Therapeutics Key Stats

Sell
26
Structure Therapeutics (GPCR) is a Sell
Day range:
$29.93 - $33.75
52-week range:
$26.61 - $66.38
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.92%
Volume:
489.3K
Avg. volume:
754.5K
1-year change:
-38.81%
Market cap:
$1.7B
Revenue:
$0
EPS:
$-2.19

How Much Does Structure Therapeutics Make?

Data Unavailable

Is Structure Therapeutics Growing As A Company?

Data Unavailable

Structure Therapeutics Stock Price Performance

What Is Structure Therapeutics 52-Week High & Low?

Structure Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Structure Therapeutics?

Is Structure Therapeutics Cash Flow Positive?

  • What Is GPCR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$101.9M
  • What Is Structure Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $796.3M
  • What Is Structure Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$572.9M

Structure Therapeutics Return On Invested Capital

Data Unavailable

Structure Therapeutics Earnings Date & Stock Price

Structure Therapeutics Competitors

Structure Therapeutics Dividend Yield

Structure Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -7.14%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 85.82
Upside from Last Price: 162.36%

Major Shareholders

  • How many GPCR shares are owned by institutional investors?
    130.6M GPCR shares are owned by institutional investors
  • How many GPCR shares are owned by insiders?
    2.2M GPCR shares are owned by insiders